PCOS is the leading cause of anovulatory infertility worldwide, and in Indian fertility clinics roughly one in three women coming in for help to conceive will have PCOS as the primary diagnosis. The mechanism is straightforward to explain: the hormonal imbalance of PCOS (excess LH, raised androgens, insulin resistance) interferes with the normal monthly maturation and release of an egg from the ovary, so cycles either stretch out to 35-60 days or skip altogether for months at a time. Without ovulation there is no egg for the sperm to meet, and pregnancy cannot happen however many months a couple tries.

Around 70% of women with PCOS report some difficulty conceiving, but this number deserves nuance. Many of those women conceive in their first or second year of trying with no treatment at all, especially if cycles are only mildly irregular. Others need a few cycles of letrozole or clomiphene and conceive within six months of starting. A smaller group needs IUI or IVF. The honest framing for a newly diagnosed woman is that PCOS is not a sentence of infertility, it is a strong prompt to plan pregnancy with awareness, to seek help earlier rather than later (after 6-12 months of trying rather than the usual 12), and to expect that treatment will work — because for the great majority of Indian women with PCOS, it does.

For women with PCOS who are overweight or obese, lifestyle modification is the genuine first-line of fertility treatment, and the data is striking: a 5-10% reduction in body weight restores ovulation in roughly half of women with PCOS, often without any medication at all. The mechanism is that fat tissue produces estrogen and worsens insulin resistance, both of which suppress ovulation, so even modest weight loss can re-set the hormonal balance and bring back regular cycles. For an Indian woman weighing 70 kg, losing 4-7 kg is enough to make a meaningful difference, and the same principle applies at every weight band.

The Indian-friendly approach centres on a low-glycaemic-index diet built around millets like ragi jowar and bajra in place of white rice and refined wheat, generous vegetables, dal and paneer for protein, and moderation of sweets fried snacks and sugary chai. Add 150 minutes a week of moderate exercise (brisk walking, cycling, swimming, prenatal-safe yoga), prioritise 7-8 hours of sleep, and treat stress as a hormonal issue not a personality trait. The results take 3-6 months to show in cycle regularity, so patience matters. For a deeper dive into PCOS lifestyle and treatment see PCOS Treatment Options in India: A Practical, Step-by-Step Guide.

Metformin (Glycomet, Glyciphage, Obimet and other brands, costing roughly Rs 50-150 for a month's supply) is widely prescribed by Indian fertility specialists as part of PCOS care, particularly when insulin resistance is documented or strongly suspected. By improving the body's response to insulin and lowering circulating insulin levels, metformin indirectly lowers ovarian androgen production and can restore spontaneous ovulation in around a quarter of women with PCOS without any other fertility medication. The typical starting dose is 500 mg once daily with the largest meal, increased gradually over 2-4 weeks to 1500-2000 mg per day in divided doses to minimise the common gastrointestinal side effects of nausea, bloating and loose stools.

Metformin works best in combination with lifestyle measures, and is often continued alongside letrozole or clomiphene as a way of improving overall response to ovulation induction. It is not a fertility drug in the strict sense — it does not directly cause ovulation in the way letrozole does — but it improves the hormonal environment in which ovulation and pregnancy can happen. Most Indian OBs and fertility specialists are comfortable continuing metformin into the first trimester if pregnancy is achieved, given a body of evidence supporting safety, though this is an individual decision with the treating doctor.

Letrozole (sold in India as Letoval, Fertyl-L, Letovar and Femara, costing roughly Rs 50-200 for a strip of 5 tablets of 2.5 mg) has become the first-line ovulation induction drug for PCOS over the last decade, displacing clomiphene from that role. The landmark PCOSMIC and NIH Reproductive Medicine Network trials showed that letrozole produces more live births in women with PCOS than clomiphene does, with comparable safety. The typical regimen is 2.5 mg once daily from days 2 to 6 of the menstrual cycle, increasing to 5 mg in the next cycle if ovulation does not occur, and occasionally to 7.5 mg.

Ovulation rates with letrozole in PCOS are around 75-85% per cycle, and pregnancy rates are around 25-30% per cycle in women who ovulate, with cumulative pregnancy rates over 6 cycles approaching 60-70%. Side effects are typically mild — hot flushes, headaches, occasional fatigue — and are much better tolerated than clomiphene's mood and visual side effects. Monitoring is usually with a mid-cycle transvaginal ultrasound to confirm follicle development, and timed intercourse or IUI is planned around the predicted ovulation day. Most Indian fertility specialists run 3-6 cycles of letrozole before considering a step-up. For broader information on ovarian assessment see AMH Test and Ovarian Reserve Testing in India: What It Means, When to Test, and Costs.

Clomiphene citrate (sold in India as Fertyl, Clofert, Ovofar and Siphene, costing roughly Rs 50-200 for a strip) was the standard first-line ovulation induction drug for decades and remains widely used in Indian fertility practice, particularly in smaller centres or when letrozole is not available. The typical dose is 50 mg once daily from days 2 to 6 of the cycle, stepped up to 100 mg and occasionally 150 mg if ovulation does not occur. Ovulation rates with clomiphene in PCOS are around 70-75%, but pregnancy rates are lower than with letrozole because clomiphene thins the endometrial lining and dries cervical mucus, both of which work against implantation.

Side effects include mood swings, hot flushes, breast tenderness, occasional visual disturbances (which require stopping the drug), and a small but real increase in the risk of twins (around 5-10% versus 1-2% with natural conception). The international consensus is that clomiphene should be limited to a maximum of 6 cycles in any one woman because cumulative use beyond that does not improve pregnancy rates and may carry a small theoretical increase in ovarian cancer risk. If clomiphene fails to achieve pregnancy after 6 cycles, the standard step is to switch to letrozole or to move up to gonadotropins or IUI.

When letrozole and clomiphene fail to produce ovulation or pregnancy after several cycles, the next step is injectable gonadotropins — recombinant FSH (Gonal-F, Recagon, Folisurge) or urinary FSH and HMG preparations (Menopur, IVF-M), costing roughly Rs 500-1500 per dose in India. These are direct hormonal stimulation of the ovaries to recruit and grow follicles, and require close monitoring with frequent transvaginal ultrasound scans (usually every 2-3 days) and serum estradiol measurements to track follicle development and prevent overstimulation.

The risk of ovarian hyperstimulation syndrome (OHSS) is meaningfully higher in PCOS women because of their large pool of small follicles, and protocols are deliberately conservative — low starting doses, slow incremental increases, and willingness to cancel a cycle if too many follicles develop. Multiple pregnancy risk is also higher (10-30% twins or triplets depending on protocol) which is why gonadotropin cycles in PCOS are usually combined with IUI rather than timed intercourse, to allow better control. The cost of a single gonadotropin-stimulated cycle in India ranges from Rs 15,000 to Rs 40,000 depending on dose and duration, and most specialists run 3-4 cycles before recommending IVF if pregnancy has not occurred.

Intrauterine insemination (IUI) is the standard next step when oral ovulation induction with timed intercourse has not produced pregnancy after several cycles, and it is almost always combined with letrozole or low-dose gonadotropin stimulation rather than being done in a natural cycle. The procedure itself is simple: on the predicted day of ovulation, a sample of the partner's washed and concentrated sperm is placed directly into the uterine cavity through a thin catheter, bypassing the cervix and reducing the distance the sperm needs to travel to reach the egg.

Success rates per cycle of IUI in PCOS women with ovulation induction are around 10-20% per cycle, depending on age, sperm quality and the number of cycles attempted, and cumulative success over 3-6 cycles reaches 40-50%. The cost in private Indian fertility clinics is roughly Rs 15,000-30,000 per cycle including medication, monitoring scans and the procedure itself; in larger metros like Mumbai Delhi and Bangalore costs trend to the higher end. Most fertility specialists in India run 3-6 IUI cycles before recommending IVF, beyond which cumulative success drops sharply and the cost-benefit shifts to IVF. For more on the IVF pathway see IVF in India: Cost, Process, Success Rates and What Actually Happens.

IVF (in-vitro fertilisation) is the definitive step in PCOS fertility care when earlier treatments have not worked, and PCOS women generally do very well in IVF because of their large pool of available follicles. Major Indian chains including Apollo Fertility, Nova IVF, Indira Hospital, Bloom IVF and Cloudnine charge roughly Rs 1.5-3.5 lakh per IVF cycle including medications, with ICSI (intracytoplasmic sperm injection) adding Rs 30,000-50,000 if male-factor issues are also present. Frozen embryo transfer cycles cost an additional Rs 50,000-1,00,000.

PCOS-specific IVF protocols use the antagonist protocol in preference to long agonist protocols because antagonist cycles carry a lower risk of OHSS, which remains the main complication concern in PCOS-IVF. Freeze-all strategies (where all good embryos are frozen and transferred in a later cycle rather than fresh) further reduce OHSS risk and have similar or better pregnancy rates. Per-cycle live birth rates in good Indian centres for women under 35 with PCOS are around 40-50%, dropping to 25-35% in the late 30s and 10-20% over 40. Cumulative success over 2-3 cycles often reaches 60-70% in younger women, making IVF a genuinely high-probability option when other paths have not worked.

For PCOS fertility care the right specialist is a fertility specialist (reproductive endocrinologist) who is a member of the Indian Society for Assisted Reproduction (ISAR) and ideally has fellowship training in reproductive medicine. General gynaecologists can manage simple letrozole cycles for mild PCOS, but anything that requires gonadotropin stimulation, IUI or IVF needs a specialist centre. The major Indian chains with strong PCOS fertility programmes include Apollo Fertility (across most metros), Nova IVF Fertility (Mumbai Delhi Bangalore Hyderabad Chennai Pune), Indira IVF (largest national network), Bloom IVF (Mumbai), and Cloudnine Fertility (Bangalore and other metros), with consultation fees typically Rs 800-2500.

What to look for in a fertility centre includes ISAR membership, transparent reporting of cycle success rates (not just pregnancy rates but live birth rates broken down by age), a clear written cost breakdown before starting, the ability to handle PCOS-specific protocols, and good counselling and emotional support — IVF in particular is hard emotionally as well as financially, and the human side of the clinic matters. Avoid centres that pressure quick decisions, refuse to share their actual success rates by age, or quote a flat package price without itemised breakdown.

The complete PCOS fertility pathway in India in 2026 rupees runs roughly as follows. Lifestyle and metformin: Rs 500-2000 per month for clinic visits and medication. Letrozole or clomiphene with monitoring scans: Rs 3000-8000 per cycle (medication Rs 100-300, two monitoring ultrasounds Rs 1500-3000 each, follow-up consultation Rs 500-1500). IUI with ovulation induction: Rs 15,000-30,000 per cycle. Gonadotropin-stimulated IUI: Rs 30,000-50,000 per cycle. IVF without ICSI: Rs 1.5-2.5 lakh per cycle. IVF with ICSI: Rs 2-3.5 lakh per cycle. Frozen embryo transfer: an additional Rs 50,000-1,00,000.

Insurance coverage for fertility treatment in India is improving but remains limited and inconsistent. Some private insurers (Star, HDFC ERGO, Bajaj Allianz, Niva Bupa) now cover fertility treatment under maternity riders or as part of premium plans, typically with lifetime limits of Rs 1-3 lakh and waiting periods of 2-4 years. Ayushman Bharat covers some IVF in select states (Tamil Nadu, Andhra Pradesh, Telangana and Maharashtra have started limited public IVF schemes), but coverage is restricted to specific income brackets and conditions. Most Indian couples still pay out of pocket for fertility treatment, and budgeting for the full pathway up to and including 1-2 IVF cycles is sensible. For detailed IVF cost information see IVF in India: Cost, Process, Success Rates and What Actually Happens.